Cerebellum’s NovoCure NVCR Stock Holding History

Cerebellum’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,236	Closed	-$300K	–	495
2019 Q1	$300K	Buy	+6,236	New	+$300K	0.26%	301

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cerebellum's NVCR Position: Q2 2019 in Review

Cerebellum sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 6,236 shares — an estimated $300K sold.

Cerebellum first reported a position in NVCR in Q1 2019 and held it in 1 quarter. The position peaked at $300K in Q1 2019. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

Cerebellum reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
Cerebellum sold 6,236 NovoCure shares in Q2 2019, an estimated $300K.
Cerebellum first reported a position in NovoCure in Q1 2019 and held it in 1 quarter.
Cerebellum's NovoCure position peaked at $300K in Q1 2019.
197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Cerebellum's 13F filing for Q2 2019, filed 19 Jul 2019.